Molecular sciences, such as chemistry, biophysics, molecular biology and protein science, are vital to innovations in medicine and the discovery of new medicines and diagnostics. As well as making a crucial contribution to health and society, industries in this field provide an essential component to the economy and contribute hugely to employment figures, currently generating nearly 500,000 jobs nationally. To enable and facilitate future economic growth in this area, the CDT will provide a cohort of researchers who have training in both aspects of this interface who will be equipped to become the future innovators and leaders in their field. All projects will be based in both molecular and medical sciences and will focus on unmet medical needs, such as understanding of disease biology, identification of new therapeutic targets, and new approaches to discovery and development of novel therapies. Specific problems will be identified by researchers within the CDT, industrial partners, stakeholders and the CDT students. The research will be structured around three theme areas: Biology of Disease, Molecule and Assay Design and Structural Biology and Computation. The CDT brings together leading researchers with a proven track record across these areas and who have pioneered recent advances in the field, such as multiple approved cancer treatments. Their combined expertise will provide supervision and mentorship to the student cohort who will work on projects that span these research themes and bring their contributions to bear on the medical problems in question. The student cohort approach will allow teams of researchers to work together on joint projects with common goals. Projects will be proposed between academics, industrial partners and students with priority given to those with industrial relevance. The programme of research and training across the disciplines will equip graduates of the CDT with an unprecedented background of knowledge and skills across the disciplines. The programme of research and training across the disciplines will be supplemented by training and hands-on experiences of entrepreneurship, responsible innovation and project management. Taken together this will make graduates of the CDT highly desirable to employers, equip them with the skills they need to envisage and implement future innovations in the area and allow them to become the leaders of tomorrow. A structured and highly experienced management group, consisting of a director, co-directors, theme leads and training coordinators will oversee the execution of the CDT with the full involvement of industry partners and students. This will ensure delivery of the cohort training programme and joint events as well as being accountable for the process of selection of projects and student recruitment. The management team has an established track record of delivery of research and training in the field across industry and academia as well as scientific leadership and network training coordination. The CDT will be delivered as a single, fully integrated programme between Newcastle and Durham Universities, bringing together highly complementary skills and backgrounds from the two institutions. The seamless delivery of the programme across the two institutions is enabled by their unique connectivity with efficient transport links and established regional networks. The concept and structure of the CDT has been developed in conjunction with the industrial partners across the pharmaceutical, biotech and contract research industries, who have given vital steer on the desirability and training need for a CDT in this area as well as to the nature of the theme areas and focus of research. EPSRC funding for the CDT will be supplemented by substantial contributions from both Universities with resources and studentship funding and from industry partners who will provide training, in kind contribution and placements as well as additional studentships.

Neurological diseases cause a substantial and increasing personal, social and economic burden. Although there have been exceptions, there is increasing frustration at the limitations of learning from animal models, emphasising the importance of studying human tissue. Neuropathologists work in NHS hospitals examining samples from the brain and related tissues derived from operations (biopsies) or post mortem examinations. Their job is to identify abnormalities, make a diagnosis and try to understand how the abnormalities arise. Neuropathology has existed as a specialty in the UK for 40-50 years and, as a consequence of this work, substantial archives of diagnostically verified tissue have been established nationwide. These archives contain a wealth of tissue from a great variety of neurological conditions, including common conditions such as stroke, head injury, tumours, infections, psychiatric disorders, developmental disorders and many rare conditions, and represent an underutilised resource for research. BRAIN UK (the UK BRain Archive Information Network) networks the tissue archives of neuropathology departments based in 26 regional NHS Clinical Neuroscience Centres to form a virtual brain bank, acting as a "matchmaker" linking researchers needing tissue to the appropriate samples. Through BRAIN UK researchers can gain access to >400,000 samples from a wide range of diseases affecting the brain, spinal cord, nerve, muscle and eye. BRAIN UK has ethical approval which covers the majority of projects, saving the researchers considerable time as they would otherwise have to obtain this approval independently. Over the past 4 years BRAIN UK has supported 48 research projects in many centres around the UK and overseas. In the coming 4 years we want to continue to provide tissue to researchers from existing resources and add newly obtained samples of which >16,000 are becoming available each year. We also aim to gather the results of researchers' studies performed on tissue obtained through BRAIN UK to form a central register of findings which will benefit new researchers wanting to perform new studies on these tissue samples. Finally, we will link BRAIN UK with UK Biobank, which has 500,000 intensively studied participants from the general population, in order to learn more about the origins of neurological disease. As far as we are aware, the BRAIN UK network is unique in the world and is very economical as it makes use of tissue samples already being stored in NHS archives which would otherwise be unused and unavailable to researchers.

The Northern Health Futures (NortHFutures) hub aims to create a world-leading healthcare technology (health-tech) development ecosystem. This will address unmet health needs and inequalities by supporting: inclusive digital skills training and sharing; research, innovation and entrepreneurship, enabled by digital design. Based in the North East and North Cumbria (NENC), with national and global reach, NortHFutures will support underserved communities, as it is known that national disparity of investment in NENC negatively impacts population health and wellbeing, and that a 'levelling up' of investment is needed to stimulate socio-economic and cultural growth for all, to encourage living and ageing well. NortHFutures builds upon the joined-up NENC approach to people-powered digital health innovation, as our regional Integrated Care Board (ICB) uniquely involves local authorities, communities, and citizens. Academic team members have a research track record that is stakeholder-involved and civic- and community-engaged. They are world-leading on understanding (i) health inequalities from medical, social, and design perspectives, and (ii) the opportunities for enrichment and enablement related to ageing well, connecting rural and urban populations, and pioneering applications of data science. In the pilot phase, we draw on this specialist expertise to address evidenced unmet health needs in NENC, (which have national and global importance): children and young people's health and nutrition; mental health and wellbeing; development of digital surgical pathways (for monitoring patient journeys beyond the hospital); living well with multiple long-term conditions. We combine the strengths and resources of 6 universities (Newcastle, Cumbria, Durham, Northumbria, Sunderland and Teesside), bringing regional investment in NIHR services, facilities and Applied Research Collaborations, plus National Innovation Centres for Ageing (NICA), Data (NICD) and Rural Enterprise (NICRE), National Horizons Centre (NHC), EPSRC Digital Economy programmes in data and digital citizens, and Health Data Research UK, the UK's national institute for health data science. NortHFutures supports new planned Centres, including Northumbria's Centre for Health & Social Equity and Cumbria's new campus and medical school. These University offers combine with an extensive partner network, including: ICB-NENC, 7 NHS Trusts, NHS Business Services Authority, Department of Health and Social Care, Health Education England; VCSE organisations delivering community-based services; industry partners - from SMEs to global tech giants; civic bodies such as Local and Combined Authorities; existing health research networks (e.g. AHSN-NENC, Newcastle Health Innovation Partnership); and innovation accelerators (e.g. Innovation SuperNetwork). Through an integrated, regional approach uniting this consortium for the first time, NortHFutures ambitiously aims to establish global leadership in Digital Health. To deliver this we will develop a supportive community infrastructure. We will co-design a digital brokerage service to connect and amplify partners' work, to offer and consume expertise, services and facilities (supporting acceleration of health-tech companies at differing tech-readiness levels). We will pioneer a Live Digital Health Databank, to explore, and train for, advanced healthcare data analytics, combining live data flows with care records (e.g. Great North Care Record). This will support personalised health diagnostics and interventions, giving our hub a unique value proposition to companies wishing to explore advanced data technologies. We will invest in Extended Reality pilots, to open up possibilities for clinical practice and service delivery. Our approaches will embed Responsible Research and Innovation (RRI), and Patient and Public Engagement (PPIE) throughout, to deliver health-tech that supports care beyond the hospital and is co-designed with end-users.

Over 200 million patients (pts) worldwide have fatigue, widespread muscle pain, joint and chest pain due to COIVD-19 infection. Little is known on onset, pathophysiology and clinical history of chronic pain post-COVID, leaving doctors at loss when it comes to specifically identify and diagnose pts and prescribe most effective treatments. To advance knowledge on post-COVID chronic pain, to discuss current clinical gaps, develop potential solutions for these pressing issues we propose a multidisciplinary consortium: -clinicians working with long COVID pts and specific knowledge of chronic post-COVID pain syndrome. -clinical experts in chronic pain syndromes in specific settings: paediatric and chronic postoperative pain, chronic pain neuromodulation; -basic scientists applying genomics for a better understanding of pain pathophysiology and using glycomics to predict long COVID and stratify the risk of pts to develop long COVID associated severe illness; -translational scientists, pharmacology and nanomedicine experts for development of new nanotherapies to tackle chronic pain, inflammation and immune activation; -startups, established biotech companies interested in development of new therapeutic tools for pain, incl.an international CDMO involved in industrialization of pharmaceutical/nutraceutical products, scientific associations (Redirect) for spreading the culture of rational approach to chronic postoperative pain and inflammatory chronic pain.